Japan is the second major market where Kisunla has received approvalKisunla was first approved in the United States in July 2024INDIANAPOLIS, Sept. 24, 2024 /PRNewswire/ -- The Ministry of Health, Labour and Welfare Japan has approved Kisunla™ (donanemab-azbt, 350 mg/20 mL every four weeks injection for IV infusion), Eli Lilly and Company's (NYSE: LLY) Alzheimer's treatment for adults with early symptomatic Alzheimer's disease (AD), which includes people with mild cognitive impairment (MCI) as well as peopl ...

Nvidia has been the hottest stock since the start of the AI revolution, and I see one particular healthcare business following a similar trajectory.Nov. 30, 2022, will go down as a defining moment in modern history. That's the day OpenAI released ChatGPT to the masses. Just like that, euphoria about artificial intelligence (AI) took over the world.One of the biggest beneficiaries of the AI boom has been semiconductor specialist Nvidia. If you had bought shares of Nvidia on the same day that ChatGPT was intr ...

I am a full-time analyst interested in a wide range of stocks. With my unique insights and knowledge, I hope to provide other investors with a contrasting view of my portfolio, given my particular background.If you have any questions, feel free to reach out to me via a direct message on Seeking Alpha or leave a comment on one of my articles.Analyst’s Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the ...

History shows that Eli Lilly tends to do something special with its stock toward the end of the year.With a market capitalization of over $800 billion, Eli Lilly (LLY 0.70%) is the largest pharmaceutical company in the world. Much that is thanks to the rise of glucagon-like peptide-1 (GLP-1) agonists such as Mounjaro and Zepbound, which are fueling a new wave of growth for the company.Over the past 12 months, its shares have soared 58% -- nearly double the gains generated from the S&P 500 and Nasdaq Composi ...

JR Research is an opportunistic investor. He was recognized by TipRanks as a Top Analyst. He was also recognized by Seeking Alpha as a "Top Analyst To Follow" for Technology, Software, and Internet, as well as for Growth and GARP. He identifies attractive risk/reward opportunities supported by robust price action to potentially generate alpha well above the S&P 500. He has also demonstrated outperformance with his picks. He focuses on identifying growth investing opportunities that present the most attracti ...

Eli Lilly stock may look expensive, but that may not be the case in a few years as the business grows at a rapid pace.Berkshire Hathaway recently crossed the $1 trillion market cap, becoming the first non-tech stock to do so. While the stock has given back some gains in recent days and fallen below that threshold, it's still an incredible accomplishment nonetheless.But there's another non-tech stock which could be worth $1 trillion in the near future, and that's Eli Lilly (LLY -0.13%). The healthcare giant ...

Lilly could take a step that's positive for the stock and investors over the long term.Eli Lilly (LLY -0.13%) offers investors the same thing as many other big pharma companies: a certain level of security when it comes to revenue. Since people need their medicines regardless of the economic environment, these players generally are linked to some earnings stability and visibility. But Lilly has stood out from the crowd in recent quarters by also giving investors something that's generally seen more in techn ...

Eli Lilly and Company’s (LLY) stock has risen 21.1% in six months compared with an increase of 10.5% for the industry. The stock has also outperformed the sector as well as the S&P 500 as seen in the chart below.LLY Stock Outperforms Industry, Sector & S&P 500    Image Source: Zacks Investment ResearchLilly has seen unparalleled success with its GLP-1 drugs, Mounjaro and Zepbound. In the past couple of years, it has received approvals for several new drugs like Kisunla, Omvoh and Jaypirca and witnessed pipe ...

Core Insights - Eli Lilly is approaching a market capitalization of $830 billion and is expected to join the trillion-dollar club soon [2] - The healthcare industry, particularly in weight loss and Alzheimer's treatment, presents significant growth opportunities for Eli Lilly [3][5] Group 1: Market Opportunities - The global total addressable market (TAM) for GLP-1 medications is projected to grow to $145 billion by 2030, increasing fourfold from current estimates [4] - The TAM for Alzheimer's treatment is expected to reach nearly $31 billion by 2033, with a compound annual growth rate (CAGR) of 19% from 2024 to 2033 [5] Group 2: Competitive Landscape - Eli Lilly is positioned uniquely in the healthcare sector, with a focus on GLP-1 drugs and Alzheimer's treatment, while other pharmaceutical companies are also entering the weight loss market [4][5] - The company has received FDA approval for its Alzheimer's treatment, donanemab, enhancing its competitive edge in a fragmented market [5] Group 3: Strategic Initiatives - Eli Lilly has formed a strategic partnership with OpenAI to integrate generative AI into healthcare, aiming to improve clinical trial data processing and drug discovery [6] - The company continues to innovate and explore new areas beyond its current offerings, indicating a strong growth trajectory [8]

Eli Lilly (LLY) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of the factors that might affect the near-term performance of the stock.Over the past month, shares of this drugmaker have returned +0.2%, compared to the Zacks S&P 500 composite's +1.5% change. During this period, the Zacks Large Cap Pharmaceuticals industry, which Lilly falls in, has gained 1.5%. The key question now is: What could be the stock's future direction?Although media report ...